Loading
A phase 1 trial of Nelitolimod run by TriSalus Life Sciences, Inc., active, not recruiting.
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma is a phase 1 interventional study registered as NCT05607953 by TriSalus Life Sciences, Inc., with 60 participants planned, started 2023-03-01, primary completion expected 2027-09. Conditions recorded: Locally Advanced Pancreatic Adenocarcinoma. Interventions recorded: SD-101, anti-PD-1.
Shares Nelitolimod, TriSalus Life Sciences and the tag pipeline.
Shares Nelitolimod, TriSalus Life Sciences and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/